Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSH3 siRNA
- Development stage
- Preclinical
- Lead developer
- Thermo Fisher Scientific
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
SSH3 siRNA is a gene-silencing tool designed to specifically target and reduce the expression of the Protein phosphatase Slingshot homolog 3 (SSH3). SSH3 is a member of the Slingshot family of phosphatases that play a critical role in regulating actin dynamics by dephosphorylating and activating cofilin. In various oncological contexts, including gastric and prostate cancers, SSH3 is often overexpressed and associated with increased cell migration, invasion, and metastasis. By utilizing the RNA interference (RNAi) pathway, SSH3 siRNA facilitates the degradation of SSH3 mRNA, thereby inhibiting the downstream activation of cofilin and potentially suppressing the invasive phenotype of malignant cells. While currently utilized primarily as a research reagent to elucidate the biological functions of SSH3 in the actin cytoskeleton, it represents a potential therapeutic strategy for targeting actin-mediated motility in cancer.
- Other names
- Slingshot-3 siRNASlingshot3 siRNASlingshot 3 siRNAsiRNA targeting SSH3SSH3-siRNASSH-3-siRNASSH 3-siRNA
02
Targets
Cytoskeleton (Cytoskeletal regulators)
Beyond the preview
Go deeper on SSH3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSH3 siRNA.